Syndax Pharmaceuticals (SNDX) EBT Margin Growth (1y) (2016 - 2026)
Analysis
Syndax Pharmaceuticals (SNDX) EBT Margin Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 553.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4,709.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1,076.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,911.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -392.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,565.00 |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.28 Bn | 60.67 Mn | 11,724.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11,724.00 |
| Mar 31, 2026 | 36,269.00 |
| Dec 31, 2025 | 107,588.00 |
| Sep 30, 2025 | 55,956.00 |
| Jun 30, 2025 | 195,761.00 |
| Dec 31, 2021 | 544,125.00 |
| Sep 30, 2021 | 519,265.00 |
| Jun 30, 2021 | -152,533.00 |
| Mar 31, 2021 | -323,799.00 |
| Dec 31, 2020 | -168,579.00 |
| Sep 30, 2020 | -199,393.00 |
| Jun 30, 2020 | -48,945.00 |
| Mar 31, 2020 | -19,077.00 |
| Dec 31, 2019 | 127,105.00 |
| Sep 30, 2019 | 121,346.00 |
| Jun 30, 2019 | 92,296.00 |
| Mar 31, 2019 | 133,193.00 |
| Dec 31, 2018 | -335,590.00 |
| Sep 30, 2018 | 35,088.00 |
| Jun 30, 2018 | -52,295.00 |